Related Experiment Video

Updated: May 3, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.4K

Core drug-drug interaction alerts for inclusion in pediatric electronic health records with computerized prescriber

Marvin B Harper1, Christopher A Longhurst, Troy L McGuire

  • 1From the *Divisions of Emergency Medicine and Infectious Diseases, Boston Children's Hospital Boston, MA, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; †Department of Clinical Informatics, Lucile Packard Children's Hospital; ‡Department of Pediatrics, Stanford School of Medicine, Palo Alto, California; §Hospitalist Division, Seattle Children's Hospital and Department of Pediatrics, University of Washington, Seattle, Washington; ∥Division of Pediatric Critical Care, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota; ¶Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and #Department of Pharmacy, Boston Children's Hospital, Boston, Massachusetts.

Journal of Patient Safety
|February 14, 2014
PubMed

Insights

A core list of 19 high-priority pediatric drug-drug interaction (DDI) pairs was developed. These are recommended for electronic alerts in prescriber order entry systems to improve pediatric patient safety.

Area of Science:

  • Clinical Informatics
  • Pediatric Pharmacology
  • Patient Safety

Background:

  • Electronic health records (EHRs) are crucial for medication safety.
  • Pediatric drug-drug interactions (DDIs) require specific attention due to unique patient factors.
  • Current DDI alert systems may not effectively prioritize high-risk interactions in pediatrics.

Purpose of the Study:

  • To establish a consensus-based core set of pediatric drug-drug interaction (DDI) pairs.
  • To identify DDIs critical for electronic alert implementation in pediatric prescribing.
  • To enhance the utility of clinical decision support systems for pediatric medication safety.

Main Methods:

  • Convened a working group of pediatric pharmacists and chief medical information officers from the Children's Hospital Association (CHA).
  • Utilized a consensus-driven approach to identify and prioritize key pediatric DDI pairs.
  • Focused on actionable DDIs for integration into electronic prescribing workflows.

Main Results:

  • Achieved consensus on a core set of 19 essential pediatric DDI pairs.
  • These 19 DDI pairs are deemed high-value for electronic alert presentation.
  • The identified DDIs represent critical interactions for pediatric patients.

Conclusions:

  • A validated core list of 19 high-value pediatric DDI pairs has been established.
  • These DDIs are recommended for inclusion in computerized prescriber order entry (CPOE) systems.
  • Implementation of these alerts aims to optimize medication safety in pediatric populations.
Abstract

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K